GF
VYGR icon

Gabelli Funds’s Voyager Therapeutics VYGR Stock Holding History

Gabelli Funds’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,481
Closed -$43K – 1444
2021
Q3 		$43K Hold
16,481
– – ﹤0.01% 1314
2021
Q2 		$68K Hold
16,481
– – ﹤0.01% 1293
2021
Q1 		$78K Buy
+16,481
New +$112K ﹤0.01% 1276

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gabelli Funds's VYGR Position: Q4 2021 in Review

Gabelli Funds sold out of Voyager Therapeutics (VYGR) in Q4 2021, closing a stake of 16,481 shares — an estimated $43K sold.

Gabelli Funds first reported a position in VYGR in Q1 2021 and held it in 3 quarters. The position peaked at $78K in Q1 2021. 59 funds tracked by Wall St. Rank hold VYGR as of Q4 2021.

  • Gabelli Funds reported no remaining Voyager Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gabelli Funds sold 16,481 Voyager Therapeutics shares in Q4 2021, an estimated $43K.
  • Gabelli Funds first reported a position in Voyager Therapeutics in Q1 2021 and held it in 3 quarters.
  • Gabelli Funds's Voyager Therapeutics position peaked at $78K in Q1 2021.
  • 59 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2021.

Based on Gabelli Funds's 13F filing for Q4 2021, filed 11 Feb 2022.